Dotinga, M.; Vriens, D.; van Velden, F.H.P.; Stam, M.K.; Heemskerk, J.W.T.; Dibbets-Schneider, P.; Pool, M.; Rietbergen, D.D.D.; de Geus-Oei, L.-F.; Kapiteijn, E.
Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial. Diagnostics 2022, 12, 3154.
https://doi.org/10.3390/diagnostics12123154
AMA Style
Dotinga M, Vriens D, van Velden FHP, Stam MK, Heemskerk JWT, Dibbets-Schneider P, Pool M, Rietbergen DDD, de Geus-Oei L-F, Kapiteijn E.
Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial. Diagnostics. 2022; 12(12):3154.
https://doi.org/10.3390/diagnostics12123154
Chicago/Turabian Style
Dotinga, Maaike, Dennis Vriens, Floris H. P. van Velden, Mette K. Stam, Jan W. T. Heemskerk, Petra Dibbets-Schneider, Martin Pool, Daphne D. D. Rietbergen, Lioe-Fee de Geus-Oei, and Ellen Kapiteijn.
2022. "Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial" Diagnostics 12, no. 12: 3154.
https://doi.org/10.3390/diagnostics12123154
APA Style
Dotinga, M., Vriens, D., van Velden, F. H. P., Stam, M. K., Heemskerk, J. W. T., Dibbets-Schneider, P., Pool, M., Rietbergen, D. D. D., de Geus-Oei, L.-F., & Kapiteijn, E.
(2022). Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial. Diagnostics, 12(12), 3154.
https://doi.org/10.3390/diagnostics12123154
